Company overview

CDI Bioscience, Inc. has developed an innovative technology for increased yield of bioproducts, manufactured in cellular systems. Genetic engineering technology is used to control the metabolism of cells, thus shifting the cell from replicative to production mode (RP Shift®). In particular, this technology has been designed for use in mammalian cells, unlocking their potential to produce proteins, peptides and enzymes. The current design of the technology can be readily translated to bacterial and yeast cellular systems for the production of commercial grade bioproducts.

Message from CEO

Many new therapeutic drugs are peptides or proteins produced by cells. These products replace a normal function that has been compromised or inhibit deleterious biological actions, such as uncontrolled proliferation of tumor cells. Many products, such as therapeutic monoclonal antibodies, growth factors and cytokines are manufactured in mammalian cell bioreactors. Costly media formulations and low product yields necessitate the invention of more efficient means of production. CDI Bioscience Inc. (CDI) has developed an innovative technology for increasing the yield of bioproducts generated by cellular systems. Genetic engineering technology is used to introduce a molecular switch that shifts mammalian cells from replicative to production mode (RP Shift®), thereby enhancing the potential of the modified cells to produce proteins, peptides and enzymes. We also utilize our expertise to immortalize primary cells and design cell lines that function to the desired specifications of our customers. With the sequencing of the human genome, the genes and proteins associated with all human diseases will be discovered leading to the development of biopharmaceutical-based therapies. We then foresee tremendous potential for the application of the RP Shift® technology over the next decade.